Cathie Wood Bets Big on Biotech with Intellia, Dumps DraftKings Stock
ByAinvest
Saturday, Aug 30, 2025 2:41 am ET1min read
NTLA--
Intellia Therapeutics has seen a substantial increase in its stock price, gaining 65% over the past three months. This growth is likely a factor in ARK's continued confidence in the company's future prospects, as evidenced by the fund's consistent buying of NTLA shares. The biotech firm specializes in gene editing and has been a key beneficiary of ARK's strategic pivot towards the sector [2].
Conversely, DraftKings, an online sports betting operator, has seen a 34% rise in its stock price over the same period. However, ARK has been scaling back its position in DKNG, indicating a potential strategic shift away from the company. The fund has been selling DraftKings shares across multiple ETFs over the past few weeks, suggesting a reallocation of resources to other sectors [2, 3].
The moves by ARK Invest are closely watched by investors and market watchers, as they can often influence market sentiment around the targeted stocks. The transparency of ARK's daily trade reports provides a unique insight into the investment strategies of one of the most closely followed fund managers in the industry [1, 2].
References:
[1] https://www.investing.com/news/company-news/cathie-woods-ark-buys-intellia-stock-trims-draftkings-position-93CH-4217460
[2] https://www.investing.com/news/company-news/cathie-woods-ark-buys-intellia-stock-trims-draftkings-position-93CH-4217460
[3] https://www.benzinga.com/etfs/specialty-etfs/25/08/47395443/cathie-wood-ditches-draftkings-stock-ahead-of-nfl-season-turns-to-prediction-markets-could-reshape-the-way
ARK Invest's Cathie Wood has increased her stake in biotech firm Intellia Therapeutics (NTLA) by $1.54 million, while scaling back her position in online sports betting operator DraftKings (DKNG) by $626,507. NTLA stock has gained 65% in the past three months, while DKNG has risen 34%. TipRanks analysts have a Strong Buy consensus rating for both stocks, with an average target price of $29.56 for NTLA and $55.29 for DKNG.
ARK Invest's Cathie Wood has made notable adjustments to her portfolio, with significant moves in Intellia Therapeutics (NTLA) and DraftKings (DKNG). On August 29, 2025, ARK purchased 133,015 shares of Intellia Therapeutics, amounting to $1.54 million, while simultaneously reducing its position in DraftKings by selling 12,990 shares, totaling $626,507 [2].Intellia Therapeutics has seen a substantial increase in its stock price, gaining 65% over the past three months. This growth is likely a factor in ARK's continued confidence in the company's future prospects, as evidenced by the fund's consistent buying of NTLA shares. The biotech firm specializes in gene editing and has been a key beneficiary of ARK's strategic pivot towards the sector [2].
Conversely, DraftKings, an online sports betting operator, has seen a 34% rise in its stock price over the same period. However, ARK has been scaling back its position in DKNG, indicating a potential strategic shift away from the company. The fund has been selling DraftKings shares across multiple ETFs over the past few weeks, suggesting a reallocation of resources to other sectors [2, 3].
The moves by ARK Invest are closely watched by investors and market watchers, as they can often influence market sentiment around the targeted stocks. The transparency of ARK's daily trade reports provides a unique insight into the investment strategies of one of the most closely followed fund managers in the industry [1, 2].
References:
[1] https://www.investing.com/news/company-news/cathie-woods-ark-buys-intellia-stock-trims-draftkings-position-93CH-4217460
[2] https://www.investing.com/news/company-news/cathie-woods-ark-buys-intellia-stock-trims-draftkings-position-93CH-4217460
[3] https://www.benzinga.com/etfs/specialty-etfs/25/08/47395443/cathie-wood-ditches-draftkings-stock-ahead-of-nfl-season-turns-to-prediction-markets-could-reshape-the-way

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue



Comments
No comments yet